Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 30 March 1984:
Vol. 223. no. 4643, pp. 1412 - 1414
DOI: 10.1126/science.6367046
Prev | Table of Contents | Next

Articles

Science, Vol 223, Issue 4643, 1412-1414
Copyright © 1984 by American Association for the Advancement of Science

articles

Biological activity of recombinant human interleukin-2 produced in Escherichia coli

SA Rosenberg, EA Grimm, M McGrogan, M Doyle, E Kawasaki, K Koths, and DF Mark

The gene for interleukin-2 was isolated from the Jurkat cell line and from normal peripheral blood lymphocytes and, when inserted in Escherichia coli, was expressed at high concentrations. This interleukin-2 was purified to apparent homogeneity and tested for biological activity in a variety of assays in vitro and in vivo. The recombinant lymphokine supports the growth of murine and human interleukin-2 dependent cell lines, enhances the generation of murine and human cytolytic cells in vitro, and generates lymphokine activated killer cells from murine and human lymphocytes. It has a serum half-life of 2 to 3 minutes in the mouse and significantly enhances the generation of cytolytic cells in vivo after alloimmunization. No functional differences between native and the recombinant interleukin-2 molecules have been detected.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
IL-4 Exacerbates Anaphylaxis.
R. T. Strait, S. C. Morris, K. Smiley, J. F. Urban Jr., and F. D. Finkelman (2003)
J. Immunol. 170, 3835-3842
   Abstract »    Full Text »    PDF »
CD4 Ligation Promotes the IL-4-Independent Development of IL-4-Producing Clones from Naive CD4+ T Cells.
S. B. Campbell, T. Komata, and A. Kelso (2001)
J. Immunol. 167, 5610-5619
   Abstract »    Full Text »    PDF »
Complete Regression of Established Spontaneous Mammary Carcinoma and the Therapeutic Prevention of Genetically Programmed Neoplastic Transition by IL-12/Pulse IL-2: Induction of Local T Cell Infiltration, Fas/Fas Ligand Gene Expression, and Mammary Epithelial Apoptosis.
J. M. Wigginton, J.-W. Park, M. E. Gruys, H. A. Young, C. L. Jorcyk, T. C. Back, M. J. Brunda, R. M. Strieter, J. Ward, J. E. Green, et al. (2001)
J. Immunol. 166, 1156-1168
   Abstract »    Full Text »    PDF »
Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines.
K. Shimizu, R. C. Fields, M. Giedlin, and J. J. Mule (1999)
PNAS 96, 2268-2273
   Abstract »    Full Text »    PDF »
X-Linked Agammaglobulinemia Patients Are Not Infected with Epstein-Barr Virus: Implications for the Biology of the Virus.
G. C. Faulkner, S. R. Burrows, R. Khanna, D. J. Moss, A. G. Bird, and D. H. Crawford (1999)
J. Virol. 73, 1555-1564
   Abstract »    Full Text »
Identification of an Essential Cis-Element Near the Transcription Start Site for Transcriptional Activation of the Proliferating Cell Nuclear Antigen Gene.
D. Y. Huang and M. B. Prystowsky (1996)
J. Biol. Chem. 271, 1218-1225
   Abstract »    Full Text »    PDF »
Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2.
S. A. Rosenberg, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White (1994)
JAMA 271, 907-913
   Abstract »    PDF »
Surgical Resection Following Interleukin 2 Therapy for Metastatic Renal Cell Carcinoma Prolongs Remission.
B. Kim and A. C. Louie (1992)
Arch Surg 127, 1343-1349
   Abstract »    PDF »
Cutaneous Histopathologic, Immunohistochemical, and Clinical Manifestations in Patients With Hemophagocytic Syndrome.
K. J. Smith, H. G. Skelton, J. Yeager, P. Angritt, K. Wagner, W. D. James, W. J. Giblin, and G. P. Lupton (1992)
Arch Dermatol 128, 193-200
   Abstract »    PDF »
Human Lymphokine-Activated Killer Cell Activity: Role of IL-2, IL-4, and IL-7.
H. Stotter and M. T. Lotze (1991)
Arch Surg 126, 1525-1530
   Abstract »    PDF »
A New Regimen of Interleukin 2 and Lymphokine-Activated Killer Cells: Efficacy Without Significant Toxicity.
T. J. Eberlein, D. D. Schoof, S.-E. Jung, D. Davidson, B. Gramolini, K. McGrath, A. Massaro, and R. E. Wilson (1988)
Arch Intern Med 148, 2571-2576
   Abstract »    PDF »
Effect of Interleukin 2 on Kupffer Cell Activation: Interleukin 2 Primes and Activates Kupffer Cells to Suppress Hepatocyte Protein Synthesis In Vitro.
R. D. Curran, T. R. Billiar, M. A. West, B. G. Bentz, and R. L. Simmons (1988)
Arch Surg 123, 1373-1378
   Abstract »    PDF »
New Approaches to the Immunotherapy of Cancer Using Interleukin-2.
S. A. ROSENBERG, M. T. LOTZE, and J. J. MULE (1988)
Ann Intern Med 108, 853-864
   Abstract »    PDF »
Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer Cells: A Phase II Clinical Trial.
R. I. FISHER, C. A. COLTMAN Jr., J. H. DOROSHOW, A. A. RAYNER, M. J. HAWKINS, J. W. MIER, P. WIERNIK, J. D. MCMANNIS, G. R. WEISS, K. A. MARGOLIN, et al. (1988)
Ann Intern Med 108, 518-523
   Abstract »    PDF »
Three-dimensional structure of interleukin-2.
B. Brandhuber, T Boone, W. Kenney, and D. McKay (1987)
Science 238, 1707-1709
   Abstract »    PDF »
Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation.
J. Reed, Y Tsujimoto, J. Alpers, C. Croce, and P. Nowell (1987)
Science 236, 1295-1299
   Abstract »    PDF »
Effects of Interleukin-2 on Renal Function in Patients Receiving Immunotherapy for Advanced Cancer.
A. BELLDEGRUN, D. E. WEBB, H. A. AUSTIN III, S. M. STEINBERG, D. E. WHITE, W. M. LINEHAN, and S. A. ROSENBERG (1987)
Ann Intern Med 106, 817-822
   Abstract »    PDF »
High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer: Responses, Treatment-Related Morbidity, and Histologic Findings.
M. T. Lotze, A. E. Chang, C. A. Seipp, C. Simpson, J. T. Vetto, and S. A. Rosenberg (1986)
JAMA 256, 3117-3124
   Abstract »    PDF »
Intraperitoneal Administration of Interleukin-2 in Patients With Cancer.
M. T. Lotze, M. C. Custer, and S. A. Rosenberg (1986)
Arch Surg 121, 1373-1379
   Abstract »    PDF »
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.
J. Mule, S Shu, S. Schwarz, and S. Rosenberg (1984)
Science 225, 1487-1489
   Abstract »    PDF »
Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues.
A Wang, S. Lu, and D. Mark (1984)
Science 224, 1431-1433
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)